Auspex Pharmaceuticals, Uniqure, Genocea Biosciences price IPOs; hot market continues
The good news is that the initial public offering (IPO) market keeps looking good for biopharma, as three more firms priced Wednesday, with two of those, both rare disease firms, pricing at the high end or above their proposed ranges. That makes nine IPOs so far this year; in comparison, only six IPOs had priced during the first four months of 2013, which turned out to be a record-breaking year for biopharma IPOs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST